ALXO stock forecast, quote, news & analysis
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials... Show more
Why ALX Oncology (ALXO) Stock Is Up +13% in the Last 30 Days
Key Takeaways
- ALX Oncology (ALXO) shares have climbed roughly +13% over the last 30 days, rebounding from a multi-year low near $0.86 reached in mid-October 2026.
- The move follows a sharp September-to-mid-October selloff triggered by a dilutive pre-funded warrant exchange agreement disclosed on October 15, 2026.
- ALX Oncology is a clinical-stage immuno-oncology company; its lead asset, evorpacept, is being developed in combination with partners including Jazz Pharmaceuticals.
- Wall Street consensus remains a Strong Buy, with an average price target near $4.60 versus a recent share price around $1.38.
- Over the last quarter, the stock is still down roughly 29%, reflecting persistent dilution and cash-burn concerns.
- Key catalysts ahead include the ASPEN-09-Breast topline readout expected in mid-2027 and ALX2004 dose-escalation safety data in the second half of 2026.
- For additional detail, explore ALXO's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading systems are approaching this ticker.
ALX Oncology (ALXO) Company Overview and Market Position
ALX Oncology Holdings Inc. (NASDAQ: ALXO) is a clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on developing novel cancer therapies that combine its lead candidate with established anti-cancer agents. Its lead product candidate, evorpacept, is a CD47-blocking therapeutic built with a high-affinity CD47-binding domain and an inactivated Fc domain, designed to be paired with anti-cancer antibodies, antibody-drug conjugates (ADCs), and PD-1/PD-L1 checkpoint inhibitors. A second program, ALX2004, is an epidermal growth factor receptor (EGFR)-targeted ADC.
Investors follow ALXO closely because evorpacept has shown encouraging signals in biomarker-selected, heavily pretreated HER2-positive cancers, with the company advancing a registrational-oriented strategy through its ASPEN-09-Breast Phase 2 trial. The company partners with larger firms such as Jazz Pharmaceuticals (zanidatamab), Merck (Keytruda), and Sanofi (isatuximab). As a pre-revenue biotech, ALX Oncology remains a high-risk, event-driven name whose valuation is tied primarily to clinical data readouts.
ALX Oncology (ALXO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ALXO shares have advanced about +13%, moving from a closing level near $1.22 in early October to roughly $1.38 as of early November. That headline gain masks a volatile path: the stock first slid into a multi-year low near $0.86 in mid-October before mounting a recovery of more than 50% off that trough.
The last quarter tells a different story. Three months ago, ALXO traded near $1.94; against a current level around $1.38, the stock is down roughly 29% over the period. In short, the recent rebound has only partially offset a deeper multi-month decline driven by financing and dilution concerns that intensified through September and early October.
What Drove ALXO Stock Price in the Last 30 Days
The dominant catalyst was a financing-related event in mid-October. On October 14, 2026, ALX Oncology entered privately negotiated exchange agreements under which certain stockholders — including funds affiliated with Blackstone Annex Master Fund L.P., RA Capital Healthcare Fund, and venBio Global Strategic Fund — agreed to surrender roughly 13.35 million shares of common stock in exchange for an equal number of pre-funded warrants carrying a $0.001 exercise price. The arrangement was disclosed in an 8-K on October 15, 2026, and the market reacted negatively to the perceived dilution, sending shares to an intraday low near $0.86.
The subsequent rebound reflected several factors. Analyst support remained intact: H.C. Wainwright reiterated a Buy rating with a $4.00 target on October 1, and Wells Fargo maintained a Buy rating with a $5.00 target on October 16. With consensus at Strong Buy and an average target near $4.60, bargain-buying and momentum-driven trading in a low-float, sub-$2 micro-cap helped lift shares off their lows, even as the broader market and yields turned risk-off on several sessions.
What Drove ALXO Stock Performance Over the Last Quarter
The quarterly decline reflects a broader narrative of cash-burn and dilution pressure for a pre-revenue clinical-stage biotech. Despite reporting a narrower Q2 2026 net loss and reiterating a cash runway into the first half of 2028, ALXO continued to face investor concerns about future financing needs. The company completed a $150 million registered offering in February 2026 at $1.57 per share, and the October warrant exchange added to the dilutive overhang. Technical deterioration also contributed, with the 50-day moving average crossing below the 200-day moving average in early October, reinforcing negative momentum before the mid-month capitulation and subsequent snap-back.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI-powered trading bots. Tickeron offers hundreds of automated trading bots that monitor thousands of tickers, but only the top-performing and most relevant strategies appear in this section. Each bot varies in its approach, trading timeframe, and performance metrics, allowing users to compare different automated strategies rather than relying on a single signal. For traders interested in how algorithmic systems are positioned across the market — including names in the biotechnology space — the page provides a useful, data-driven starting point for further research.
ALXO Stock Forecast Drivers: What Investors Should Watch Next
Several milestones are likely to shape ALXO's trajectory. The company expects topline data from its Phase 2 ASPEN-09-Breast trial (approximately 80 patients) in mid-2027, while dose-escalation safety data for the ALX2004 ADC program is anticipated in the second half of 2026. Quarterly earnings updates — with the next report expected in early-to-mid November 2026 — will provide a read on spending discipline and cash position after management reiterated a runway into the first half of 2028. Macro conditions, including interest rates and risk appetite for speculative biotech, plus any future financing or dilution events, remain key swing factors. As always with clinical-stage companies, trial outcomes and regulatory developments carry the greatest binary risk.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALXO in +11.74% Uptrend, growing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ALXO advanced for three days, in 212 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALXO's RSI Indicator exited the oversold zone, 34 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on ALXO as a result. In 68 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for ALXO just turned positive on October 19, 2026. Looking at past instances where ALXO's MACD turned positive, the stock continued to rise in 29 of 40 cases over the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 46 cases where ALXO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALXO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALXO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALXO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. ALXO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.173) is normal, around the industry mean (3.498). P/E Ratio (-1.004) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALXO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical stage company, which engages in the research and development of therapies for cancer patients
Industry Biotechnology